Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) – Equities researchers at Zacks Investment Research increased their FY2018 earnings per share (EPS) estimates for Ampliphi Biosciences in a research note issued to investors on Thursday, November 29th. Zacks Investment Research analyst D. Bautz now forecasts that the biotechnology company will earn ($0.54) per share for the year, up from their previous forecast of ($0.68). Zacks Investment Research also issued estimates for Ampliphi Biosciences’ Q4 2018 earnings at ($0.09) EPS, FY2019 earnings at ($0.31) EPS and FY2020 earnings at ($0.29) EPS.
Separately, HC Wainwright set a $4.00 price objective on Ampliphi Biosciences and gave the company a “buy” rating in a research report on Friday, November 9th.
Shares of NYSEAMERICAN:APHB opened at $0.27 on Monday. Ampliphi Biosciences has a 1 year low of $0.21 and a 1 year high of $2.05.
Ampliphi Biosciences (NYSEAMERICAN:APHB) last announced its quarterly earnings results on Thursday, November 8th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02.
About Ampliphi Biosciences
AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections.
See Also: Liquidity
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.